Ultrasis Share Discussion Threads

[humphries1] 23/6/2017 08:21

hi wooly regarding OPTI if you dont want to read to many posts on OPTI just read the posts from ELRICO he knows his stuff

[wulwirth] 17/6/2017 09:52

John Boy you didn't block this.

[wulwirth] 13/6/2017 21:08

Smith has google news blocked, odd bit from other source btb.

[wulwirth] 06/6/2017 06:42

Hope so mate, you deserve it :)

Smith's done a great job of concealing company progress, Google news block for sure!

[thechainman] 31/5/2017 21:27

watch speedy wooly gonna fly

[wulwirth] 24/5/2017 15:47

Alan Kershaw and crew ready to float Velocity Composite.

Symbol VEL.



Same job as Ultrasis Alan Kershaw - Chief Financial Officer...

Alan joined Velocity as Chief Financial Officer in March 2016 having previously held senior roles in other AIM quoted companies. Alan was finance director of Ultrasis plc from June 2014 to October 2015

[humphries1] 19/5/2017 08:15

hi wooly yes fantastic, and a hell of a lot more to come

[wulwirth] 18/5/2017 19:35

Nice little recovery :)

[wulwirth] 17/5/2017 10:19

Thanks humph, its on my lse watchlist.

[humphries1] 16/5/2017 15:16

wooly i can understand just keep your eye on it i am not saying buy by any means

[wulwirth] 16/5/2017 15:04

humph I remain very nervous in the aim.pain

[humphries1] 16/5/2017 07:49

hi wooly more news from OPTI
OptiBiotix Health plc

("OptiBiotix" or the "Company")

Successful Launch of LP(LDL) (R) and SlimBiome(R) products at Vitafoods 2017

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, and diabetes announces the successful launch of its SlimBiome(R) and LP(LDL) (R) products at the Vitafoods Europe tradeshow in Geneva from the 9-11 of May 2017. The event provided the opportunity to connect with 16,500 industry decision makers from the supplements, nutraceutical, functional food and beverage industries. This is viewed as one of the world's leading trade fairs for the food and drinks industry.

OptiBiotix launched the first of its range of heart health products containing LP(LDL) (R) called CholBiome and CardioBiome, and its SlimBiome(R) weight management technology. Both product types were exhibited in the New Products Zone and at Sacco's and Nutrilinea's stands. Sacco and Nutrilinea are OptiBiotix's European manufacturing and formulation partners and have an extensive European network to maximise the commercial opportunity provided by these products.

Both LP(LDL) (R) and SlimBiome(R) were extremely well received with high interest in the distribution and sale of these products from partners across Europe, Japan, India, Asia, Australia and the USA. OptiBiotix's recent appointments, Commercial Director Per Rehne, and Sales and Marketing Director Christina Wood, are leading the commercialisation and internationalisation of these products in global markets. Christina is leading the commercialisation of SlimBiome whilst Per is leading the commercialisation of LP(LDL) (R).

Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased with the very high level of interest from both national and multinational companies interested in selling our products. This has already resulted in some companies sending through draft contracts. The Company anticipates that this interest will start to generate revenues from both ingredient supply, and as a component in high value white label and branded formulations and presentations, across multiples territories. We are at the start of the commercialisation process but are really excited at the high level of interest in our products. We look forward to building commercial partnerships, market presence, and multiple revenue streams in both consumer health and pharmaceutical markets around the world."

[wulwirth] 14/5/2017 13:29

Bell - 10 May 17.

[wulwirth] 10/5/2017 10:33

Did you notice bells name and bet666 has vanished, he's now sole director of metro play.

[humphries1] 10/5/2017 08:51

hi wooly its hard to know what the future holds with young companies, but i think the way health will be treated is the way things are going to go in the future, and we have great products in the pipeline.
humph

[wulwirth] 09/5/2017 15:51

Good report Humph, glad I didn't buy on high and get tied like many aim stocks, be very careful mate.

[humphries1] 09/5/2017 07:18

hi wooly
news from OPTI

09 May 2017

OptiBiotix Health plc

("OptiBiotix" or the "Company")

LP(LDL) (R) Non-Exclusive European License Agreement

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has agreed to grant a non-exclusive license agreement to Nutrilinea for the production and commercialisation of products containing OptiBiotix's LP(LDL) (R) strain in Europe with a view to maximising the financial return for both parties.

Nutrilinea has over 15 years' experience in the design and development of customised formulations and presentations (capsules, tablets, sachets) for the supplement and pharmaceutical industry. Nutrilinea provides products to both national and international businesses in Europe and the USA, and is one of Europe's fastest growing providers of food supplements, doubling revenues in the last 12 months to over EUR30m per annum.

Nutrilinea is based in Italy and has established an international reputation for providing innovative product formulations and presentations for different markets, including products containing some of the world's best selling probiotic strains. Nutrilinea intends to produce proprietary formulations containing OptiBiotix's LP(LDL) (R) strain developed to reduce cholesterol levels and blood pressure (CholBiome(TM)), and cardiovascular risk (CardioBiome(TM)). Under the terms of the agreement, Nutrilinea intends to produce, promote, market and commercialise OptiBiotix's CholBiome(TM) and CardioBiome(TM) products to their European network with the aim of maximising the financial return for both parties.

This pre-launch agreement is another step in a business to business (B2B) strategy of bringing OptiBiotix's science together with partner's expertise and market reach to serve multiple consumer healthcare and pharmaceutical markets around the world.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this non-exclusive license agreement with Nutrilinea for the production and commercialisation of products containing OptiBiotix's LP(LDL) (R) strain for the reduction of cholesterol and cardiovascular risk. We chose Nutrilinea due to its industry reputation, extensive European network, and record of doubling revenues in the last 12 months. We believe working with Nutrilinea, and similar partners around the world, provide the best opportunity of building LP(LDL) (R) into a global brand. We see this as another step in building revenues and market presence of LP(LDL) (R) as the 'Intel' inside a wide range of products, provided in different presentations and formulations, for cardiovascular health across both consumer and pharmaceutical markets around the world."

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

[wulwirth] 06/5/2017 15:52

Bell sole director Metro Play.

[wulwirth] 02/5/2017 13:27

smith still pushing it.

[wulwirth] 01/5/2017 16:07

smith holds 18 directorships.

[wulwirth] 25/4/2017 21:54

Cheers Humph still watching them :)

[humphries1] 24/4/2017 07:48

hi wooly a litle read for you
www.proactiveinvestors.co.uk/companies/news/176222/materialising-value-for-shareholders-is-the-mantra-for-the-boss-of-life-sciences-firm-optibiotix-176222.html, good read.
advfn wont let me paste whole address